Evoke Pharma Q1 net product sales up 114% to $1.7M; reiterates $14M 2024 guidance

Evoke Pharma Inc

2024-Q1 EPS reported -$0.17 revenue$1,735,490

Net product sales of $1.7M vs $0.8M in Q1 2023; net loss of $1.6M ($0.17/share) improved from $2.2M ($0.67/share).
Prescriber count grew 70% QoQ; medication fills increased 10% in Q1 2024 despite February cyberattack on claims processor.
Raised $8.8M gross from public offering and warrant exercises; cash $9.7M expected to fund ops into Q1 2025.
Reaffirmed full-year 2024 net revenue guidance of approximately $14M.
Strengthened distribution partnership with ASPN Pharmacies and plans to present nasal metoclopramide data at DDW 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evoke Pharma Inc reported the first quarter ended March 31, 2024 results: revenue approximately $1.7 million, net income approximately $1.6 million, EPS $0.17 per share.

Period: the first quarter ended March 31, 2024
Revenue: approximately $1.7 million
Net income: approximately $1.6 million
EPS: $0.17 per share
Result: reported results

Exact text from the filing

physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.” “In the first quarter of 2024, our net revenue of approximately $1.7 million faced marginal impacts from transient challenges, including a cyberattack on the largest U.S. medical claims processor and an increase in co-pay expenses covered by Evoke. The

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.